China's capital markets under pressure from U.S. tariffs, regulator says
BEIJING, May 7 (Reuters) - The head of China's securities regulator said on Wednesday that U.S. tariff policy has brought great pressure to China's capital markets and will forcefully promote long-term capital into the stock market.
The attractiveness of Chinese assets is increasing amid global uncertainties, Wu Qing, chairman of China Securities Regulatory Commission, told a news briefing.
The Reuters Tariff Watch newsletter is your daily guide to the latest global trade and tariff news. Sign up here.
China will help A-share listed companies affected by tariffs to cope with difficulties, said Wu.
Reporting by Beijing Newsroom; Editing by Christian Schmollinger
Our Standards: The Thomson Reuters Trust Principles. , opens new tab
Share X
Link
Purchase Licensing Rights
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
44 minutes ago
- The Independent
China retaliates against EU with a ban on European medical devices
China said Sunday that European medical device companies will be barred from selling to the Chinese government as a countermeasure for the European Union's restrictions on the sale of similar products from China. European companies will be excluded if the budget for procurement is above 45 million yuan ($6.28 million), according to a notice from the Finance Ministry on Sunday with the restrictions in place the same day. The move will not apply to European companies that have invested in China and that manufacture goods in the country. China on Friday imposed anti-dumping duties on European brandy, most notably cognac produced in France. While the duties on brandy include several exceptions for major brandy producers, China and the EU have multiple trade disputes across a range of industries. China protested after many European countries levied duties on EVs made in China. Since then, China has also launched investigations into European pork and dairy products. In June, the EU announced that Chinese companies were to be excluded from any government purchases of more than 5 million euros ($5.89 million). The measure seeks to incentivise China to cease its discrimination against EU firms, the EU said, accusing China of erecting "significant and recurring legal and administrative barriers to its procurement market.' In response, China has said it had 'no choice but to implement countermeasures.' 'China has repeatedly expressed through bilateral dialogues that it is willing to properly handle differences with the EU through dialogue and consultation and bilateral government procurement arrangements,' said a statement from a spokesman with the Ministry of Commerce. 'Unfortunately, the EU has ignored China's goodwill and sincerity and still insisted on taking restrictive measures and building new protectionist barriers.'
Reuters
an hour ago
- Reuters
Nissan considers Foxconn EV output to save Oppama from closure, Nikkei says
TOKYO, July 6 (Reuters) - Nissan Motor (7201.T), opens new tab is in discussions with Taiwan's Foxconn ( opens new tab about a collaboration in electric vehicles that could save its Oppama plant in Japan from closure, the Nikkei business daily reported on Sunday, citing an unidentified Nissan source. Nissan's Oppama plant, which employs about 3,900 workers, has been a potential consolidation target in the struggling Japanese carmaker's restructuring plans, but the floated idea of producing Foxconn-brand EVs at its idle assembly lines could preserve the jobs and supplier networks, Nikkei said.
Reuters
an hour ago
- Reuters
Switzerland seeks trade deal with Trump without getting into EU bind
ZURICH, July 3 (Reuters) - Switzerland is exploring what concessions it can make to secure a deal with Washington on trade, but it must tread carefully to protect its interests with key trading partner, the European Union, politicians and people familiar with the matter said. The Swiss cabinet last month approved its biggest trade policy overhaul in years with the EU, two months after the U.S. stunned Switzerland by announcing 31% tariffs - well above the 20% rate Washington set out for the 27-nation bloc. That shock prompted a scramble by business leaders and officials to underline how much Switzerland invests in the United States and the tariff threat was suspended for a 90-day period ending July 9. Talks are continuing. Nicolas Walder, a Greens member of the lower house of parliament's foreign policy committee, said Switzerland must insist on its commitment to multilateralism with the U.S. "A deal should not interfere with any agreement that Switzerland has signed or wants to sign, and should specifically mention the bilateral agreement with the EU," said Walder, whose committee is regularly briefed on the trade talks. The Swiss mandate for negotiating with the U.S. stipulates that relations with its other trade partners be upheld. Any U.S. deal must be compatible with Switzerland's future relations with the EU, a Swiss source familiar with the matter said. Swiss officials and lawmakers believe that a 31% tariff can be averted, but say U.S. President Donald Trump's existing 10% baseline tariff looks likely to stay. "Switzerland is negotiating in good faith with the U.S. government, aiming for a positive outcome," the Swiss Economy Ministry said in a statement in response to questions on the points made by Reuters in this article. The EU trade agreement faces a lengthy approval process and is almost certain to be put to a national referendum under Switzerland's system of direct democracy. Trump's unpredictable approach to trade policy has been a challenge for Switzerland, which abolished its own industrial tariffs last year and sets great store by adherence to rules. Eager to offer Trump something, Switzerland is exploring granting concessions to the U.S., such as greater market access for produce like seafood and citrus fruits, the source said. Home to pharmaceutical giants Roche and Novartis - both big U.S. investors - Switzerland also knows Washington has been investigating trade practices in the sector and does not want any deal to be muddied later by pharma tariffs, the source said. "This is absolutely crucial," said Simon Michel, a federal lawmaker and CEO of medical technology company Ypsomed. Jean-Philippe Kohl, deputy director of industry association Swissmem, said even if only a 10% tariff applies, the dollar's decline against the Swiss franc amid the trade uncertainty was already making exporters' goods dearer in the U.S. And if the EU secured better tariff terms with Washington, that could put Swiss firms at a disadvantage. "It's therefore important that the dialogue with the U.S. quickly lead to a positive outcome," he said.
